Regulations.gov document
Reference 5 Suman Dandamudi, Bioequivalence Review Perspective, U.S. Food & Drug Admin…
Supporting & Related Material · FDA-2021-P-0550 · posted Jun 16, 2021
Key facts
| Document ID | FDA-2021-P-0550-0008 |
|---|---|
| Title | Reference 5 Suman Dandamudi, Bioequivalence Review Perspective, U.S. Food & Drug Admin. Public Workshop on Topical Dermatological Generic Drug Products: Overcoming Barriers to Development and Improving Patient Access and Improving Patient Access Overcoming Barriers to Development and Improving Patient Access Overcoming, (Oct. 20, 2017), at slide 3 re: Citizen Petition from Baker Hostetler on beha |
| Document type | Supporting & Related Material |
| Subtype | Background Material |
| Agency | FDA |
| Docket | FDA-2021-P-0550 |
| Posted | Jun 16, 2021 |
At a glance
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: